CLIA-waived molecular diagnostic test delivering rapid infectious disease results in approximately 15 minutes. Combines detection of influenza A/B, respiratory syncytial virus, and COVID-19 in a single assay.
Manufactured by
United States
Diasorin is an IVD manufacturer providing automated and consolidated specialty testing solutions for laboratories. The company offers a broad immunodiagnostic solution pairing LIAISON® chemiluminescent technology with consistent and easy-to-use tests, a reliable molecular portfolio with targeted and syndromic options for detecting pathogens in clinical specimens, and multiplexed-based clinical and life science research solutions. Diasorin's solutions optimize laboratory operations by consolidating, automating, and integrating workflows, enabling early diagnostic delivery to impact patient care and outcomes.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Shenzhen Uni-medica Technology Co., Ltd
China · 2 relevant products
nal von minden GmbH
Germany · 2 relevant products
LifeSign/PBM
United States · 1 relevant product
65 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →12 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 109 closest product alternatives
Shenzhen Uni-medica Technology Co., Ltd · China
A rapid diagnostic test for nucleic acid detection of influenza A, influenza B, COVID-19, and respiratory syncytial virus.
nal von minden GmbH · Germany
Multiplexed rapid antigen test for simultaneous detection of SARS-CoV-2, influenza A/B, and respiratory syncytial virus. Designed for efficient differential diagnosis of respiratory infections.
LifeSign/PBM · United States
A rapid immunoassay for simultaneous detection and differential diagnosis of SARS-CoV-2, influenza type A, and type B antigens from nasal and nasopharyngeal swab specimens. Provides results in 15 minutes with FDA 510(k) clearance and CLIA waiver status.
106 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products